Ocugen to Provide Business Update and Third Quarter 2026 Financial Results on November 4GlobeNewsWire · 3 days ago
Ocugen and Roots Pharmaceutical Complete License Agreement for OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North AfricaGlobeNewsWire · Oct 14, 2026
Did Ocugen, Inc. Insiders Breach their Fiduciary Duties to Shareholders?PRNewsWire · Oct 8, 2026
Hemostemix Announces Full LARTA Approval, Manufacturing Progress and Financing UpdateNewsfile Corp · Oct 7, 2026
Ocugen Appoints Industry Executive Jolanda Crombach General Manager of European AffiliateGlobeNewsWire · Oct 6, 2026
Ocugen to Participate in Upcoming Scientific ConferencesGlobeNewsWire · Sep 30, 2026Ocugen, Inc. is a biopharmaceutical company in the clinical development phase, primarily dedicated to pioneering gene therapies aimed at treating various ophthalmic conditions leading to blindness. The company's developmental pipeline features several key candidates: OCU400: An innovative gene therapy designed to reinstate both the function and structural integrity of the retina across a broad spectrum of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and Leber congenital amaurosis. OCU410: Another gene therapy candidate, currently being developed to address dry age-related macular degeneration (AMD).
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 6, 2026 | -$0.05 | -$0.07 | Miss |
| May 5, 2026 | -$0.05 | -$0.06 | Miss |
| Mar 4, 2026 | -$0.06 | -$0.06 | Beat |
| Nov 5, 2025 | -$0.06 | -$0.07 | Miss |
| Aug 1, 2025 | -$0.06 | -$0.05 | Beat |
| May 9, 2025 | -$0.06 | -$0.05 | Beat |